Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype.
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
27
08
2023
accepted:
10
12
2023
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
16
1
2024
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, occurring predominantly in patients with underlying chronic liver disease and cirrhosis. Here, we describe a case of a 62-year-old man that was admitted to our hospital and diagnosed with HCC where the cancer has already metastasized to the retroperitoneum and peritoneum. In order to better characterize the HCC, both the cancerous liver tissue and the adjacent normal liver tissue of the patient were collected and subjected to a genomic, transcriptomic and proteomic analysis. Our patient carries a highly mutated HCC, which is characterized by both somatic mutation in the following genes ALK, CDK6, TP53, PGR. In addition, we observe several molecular alterations that are associated with potential therapy resistance, for example the expression of the organic-anion-transporting polypeptide (OATP) family members B1 and B3, that mediate the transport of the anticancer drugs, has been found decreased. Overall, our molecular profiling potentially classify the patient with poor prognosis and possibly displaying resistance to pharmacological therapy.
Identifiants
pubmed: 38228856
doi: 10.1007/s12672-023-00850-9
pii: 10.1007/s12672-023-00850-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10Subventions
Organisme : Ministero dell'Università e della Ricerca
ID : MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia
Organisme : Ministero dell'Università e della Ricerca
ID : MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia
Organisme : Ministero dell'Università e della Ricerca
ID : MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia
Organisme : Associazione Italiana per la Ricerca contro il Cancro (AIRC)
ID : IG 2022 ID 27366; 2023-2027
Organisme : Regione Lazio
ID : LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986; n 33 & 55-2021-T0002E0001
Informations de copyright
© 2024. The Author(s).
Références
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
pubmed: 33479224
doi: 10.1038/s41572-020-00240-3
Menghini R, Hoyles L, Cardellini M, Casagrande V, Marino A, Gentileschi P, Davato F, Mavilio M, Arisi I, Mauriello A, Montanaro M, Scimeca M, Barton RH, Rappa F, Cappello F, Vinciguerra M, Moreno-Navarrete JM, Ricart W, Porzio O, Fernández-Real JM, Burcelin R, Dumas ME, Federici M. ITCH E3 ubiquitin ligase downregulation compromises hepatic degradation of branched-chain amino acids. Mol Metab. 2022;59: 101454.
pubmed: 35150905
pmcid: 8886057
doi: 10.1016/j.molmet.2022.101454
Casagrande V, Mauriello A, Anemona L, Mavilio M, Iuliani G, De Angelis L, D’Onofrio M, Arisi I, Federici M, Menghini R. Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice. Acta Diabetol. 2019;56(12):1265–74.
pubmed: 31292722
doi: 10.1007/s00592-019-01382-x
Agostini M, Mancini M, Candi E. Long non-coding RNAs affecting cell metabolism in cancer. Biol Direct. 2022;17(1):26.
pubmed: 36182907
pmcid: 9526990
doi: 10.1186/s13062-022-00341-x
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–13.
pubmed: 28481359
pmcid: 5461196
doi: 10.1038/nm.4333
Amelio I, Bertolo R, Bove P, Candi E, Chiocchi M, Cipriani C, Di Daniele N, Ganini C, Juhl H, Mauriello A, Marani C, Marshall J, Montanaro M, Palmieri G, Piacentini M, Sica G, Tesauro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G. Cancer predictive studies. Biol Direct. 2020;15(1):18.
pubmed: 33054808
pmcid: 7557058
doi: 10.1186/s13062-020-00274-3
Liu C, Kuang J, Wang Y, Duan T, Min L, Lu C, Zhang T, Chen R, Wu Y, Zhu L. A functional reference map of the RNF8 interactome in cancer. Biol Direct. 2022;17(1):17.
pubmed: 35831895
pmcid: 9277853
doi: 10.1186/s13062-022-00331-z
Liang J, Li G, Liao J, Huang Z, Wen J, Wang Y, Chen Z, Cai G, Xu W, Ding Z, Liang H, Datta PK, Chu L, Chen X, Zhang B. Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation. Cell Death Differ. 2022;29(5):988–1003.
pubmed: 35034103
pmcid: 9090725
doi: 10.1038/s41418-022-00929-w
Li X, Yuan J, Song C, Lei Y, Xu J, Zhang G, Wang W, Song G. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma. Cell Death Differ. 2021;28(8):2315–32.
pubmed: 33649471
pmcid: 8329202
doi: 10.1038/s41418-021-00754-7
Wu Y, Jiao H, Yue Y, He K, Jin Y, Zhang J, Zhang J, Wei Y, Luo H, Hao Z, Zhao X, Xia Q, Zhong Q, Zhang J. Ubiquitin ligase E3 HUWE1/MULE targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury. Cell Death Differ. 2022;29(9):1705–18.
pubmed: 35260822
pmcid: 9433446
doi: 10.1038/s41418-022-00957-6
Cao HJ, Jiang H, Ding K, Qiu XS, Ma N, Zhang FK, Wang YK, Zheng QW, Xia J, Ni QZ, Xu S, Zhu B, Ding XF, Chen TW, Qiu L, Chen W, Li ZG, Zhou B, Feng WM, Xie D, Li JJ. ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2. Cell Death Differ. 2023;30(2):383–96.
pubmed: 36396719
doi: 10.1038/s41418-022-01090-0
Liang X, Yao J, Cui D, Zheng W, Liu Y, Lou G, Ye B, Shui L, Sun Y, Zhao Y, Zheng M. The TRAF2-p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway. Cell Death Differ. 2023;30(6):1550–62.
pubmed: 37081115
pmcid: 10244464
doi: 10.1038/s41418-023-01164-7
Long S, Wang Y, Chen Y, Fang T, Yao Y, Fu K. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma. Biol Direct. 2022;17(1):28. https://doi.org/10.1186/s13062-022-00340-y .
doi: 10.1186/s13062-022-00340-y
pubmed: 36209249
pmcid: 9548146
Humpton TJ, Hall H, Kiourtis C, Nixon C, Clark W, Hedley A, Shaw R, Bird TG, Blyth K, Vousden KH. p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4. Cell Death Differ. 2022;29(3):514–26.
pubmed: 34628485
doi: 10.1038/s41418-021-00871-3
Panatta E, Butera A, Celardo I, Leist M, Melino G, Amelio I. p53 regulates expression of nuclear envelope components in cancer cells. Biol Direct. 2022;17(1):38.
pubmed: 36461070
pmcid: 9716746
doi: 10.1186/s13062-022-00349-3
Rozenberg JM, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D, Bessmertnyi A, Romanishin A, Alsoulaiman L, Kumeiko V, Kagansky A, Melino G, Ganini C, Barlev NA. The p53 family member p73 in the regulation of cell stress response. Biol Direct. 2021;16(1):23.
pubmed: 34749806
pmcid: 8577020
doi: 10.1186/s13062-021-00307-5
Panatta E, Zampieri C, Melino G, Amelio I. Understanding p53 tumour suppressor network. Biol Direct. 2021;16(1):14.
pubmed: 34362419
pmcid: 8348811
doi: 10.1186/s13062-021-00298-3
Butera A, Roy M, Zampieri C, Mammarella E, Panatta E, Melino G, D’Alessandro A, Amelio I. p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer. Biol Direct. 2022;17(1):6.
pubmed: 35255936
pmcid: 8902766
doi: 10.1186/s13062-022-00319-9
Yan Q, Zhang Y, Fang X, Liu B, Wong TL, Gong L, Liu S, Yu D, Liu M, Jiang L, Wang X, Wei T, Jia Y, Li L, Sun L, Tang Y, Zhou N, Yuan YF, Li Y, Ma S, Guan XY. PGC7 promotes tumor oncogenic dedifferentiation through remodeling DNA methylation pattern for key developmental transcription factors. Cell Death Differ. 2021;28(6):1955–70.
pubmed: 33500560
pmcid: 8185079
doi: 10.1038/s41418-020-00726-3
Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu L, Song Y, Zhou Y, Zhao X, Zhang Y, Bai Y, Pan Y, Zhang J, Shao C. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30(1):137–51.
pubmed: 35995846
doi: 10.1038/s41418-022-01051-7
Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 2022;29(3):467–80.
pubmed: 35075250
pmcid: 8901678
doi: 10.1038/s41418-022-00941-0
Zhang Y, Luo M, Cui X, O’Connell D, Yang Y. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA. Cell Death Differ. 2022;29(9):1850–63.
pubmed: 35338333
pmcid: 9433379
doi: 10.1038/s41418-022-00970-9
Zhao C, Gong J, Bai Y, Yin T, Zhou M, Pan S, Liu Y, Gao Y, Zhang Z, Shi Y, Zhu F, Zhang H, Wang M, Qin R. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Cell Death Differ. 2023;30(1):1–15.
pubmed: 35906484
doi: 10.1038/s41418-022-01040-w
Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors. Pharmaceutics. 2020;12(9):856.
pubmed: 32916864
pmcid: 7559291
doi: 10.3390/pharmaceutics12090856
Tsai HW, Ho CL, Cheng SW, Lin YJ, Chen CC, Cheng PN, Yen CJ, Chang TT, Chiang PM, Chan SH, Ho CH, Chen SH, Wang YW, Chow NH, Lin JC. Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. World J Gastroenterol. 2018;24(10):1152–66.
pubmed: 29563759
pmcid: 5850134
doi: 10.3748/wjg.v24.i10.1152
Lee SR, Lee JG, Heo JH, Jo SL, Ryu J, Kim G, Yon JM, Lee MS, Lee GS, An BS, Shin HJ, Woo DC, Baek IJ, Hong EJ. Loss of PGRMC1 delays the progression of hepatocellular carcinoma via suppression of pro-inflammatory immune responses. Cancers. 2021;13(10):2438.
pubmed: 34069911
pmcid: 8157610
doi: 10.3390/cancers13102438
Jia SW, Fu S, Wang F, Shao Q, Huang HB, Shao JY. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma. World J Gastroenterol. 2014;20(1):183–92.
pubmed: 24415871
pmcid: 3886007
doi: 10.3748/wjg.v20.i1.183
Tan AC, Tan DSW. targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–25.
pubmed: 34985916
doi: 10.1200/JCO.21.01626
Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death Differ. 2022;29(5):938–45.
pubmed: 35383292
pmcid: 9090814
doi: 10.1038/s41418-022-00980-7
Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021;21(10):619–37.
pubmed: 34316057
doi: 10.1038/s41568-021-00377-7
Degasperi A, Amarante TD, Czarnecki J, Shooter S, Zou X, Glodzik D, Morganella S, Nanda AS, Badja C, Koh G, Momen SE, Georgakopoulos-Soares I, Dias JML, Young J, Memari Y, Davies H, Nik-Zainal S. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020;1(2):249–63.
pubmed: 32118208
pmcid: 7048622
doi: 10.1038/s43018-020-0027-5
Chartron E, Theillet C, Guiu S, Jacot W. Targeting homologous repair deficiency in breast and ovarian cancers: biological pathways, preclinical and clinical data. Crit Rev Oncol Hematol. 2019;133:58–73.
pubmed: 30661659
doi: 10.1016/j.critrevonc.2018.10.012
Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, Xi SY, Zhao Y, Zhang Y, Yuan YF, Ma NF, Ma S, Guan XY, Liu M. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021;20(1):20.
pubmed: 33485358
pmcid: 7824946
doi: 10.1186/s12943-021-01315-9
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
pubmed: 28420421
pmcid: 5395719
doi: 10.1186/s13073-017-0424-2
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558–61.
pubmed: 8505985
doi: 10.1038/363558a0
Suresh A, Dhanasekaran R. Implications of genetic heterogeneity in hepatocellular cancer. Adv Cancer Res. 2022;156:103–35.
pubmed: 35961697
pmcid: 10321863
doi: 10.1016/bs.acr.2022.01.007
Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–20.
pubmed: 26880610
doi: 10.1158/1078-0432.CCR-15-1678
Bonfiglio R, Nardozi D, Scimeca M, Cerroni C, Mauriello A, Bonanno E. PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy. Future Oncol. 2017;13(24):2129–31.
pubmed: 28984478
doi: 10.2217/fon-2017-0278
Scimeca M, Bonfiglio R, Urbano N, Cerroni C, Anemona L, Montanaro M, Fazi S, Schillaci O, Mauriello A, Bonanno E. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. Urol Oncol. 2019;37(5):297.e19-297.e31.
pubmed: 30827759
doi: 10.1016/j.urolonc.2019.02.013
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–34.
pubmed: 16518375
doi: 10.1038/nrd1984
Scimeca M, Urbano N, Bonfiglio R, Mapelli SN, Catapano CV, Carbone GM, Ciuffa S, Tavolozza M, Schillaci O, Mauriello A, Bonanno E. prostate osteoblast-like cells: a reliable prognostic marker of bone metastasis in prostate cancer patients. Contrast Media Mol Imaging. 2018;9(2018):9840962.
Scimeca M, Giocondo R, Montanaro M, Granaglia A, Bonfiglio R, Tancredi V, Mauriello A, Urbano N, Schillaci O, Bonanno E. BMP-2 variants in breast epithelial to mesenchymal transition and microcalcifications origin. Cells. 2020;9(6):1381.
pubmed: 32498363
pmcid: 7348762
doi: 10.3390/cells9061381
Luk IY, Jenkins LJ, Schoffer KL, Ng I, Tse JWT, Mouradov D, Kaczmarczyk S, Nightingale R, Burrows AD, Anderson RL, Arango D, Dopeso H, Croft L, Richardson MF, Sieber OM, Liao Y, Mooi JK, Vukelic N, Reehorst CM, Afshar-Sterle S, Whitehall VLJ, Fennell L, Abud HE, Tebbutt NC, Phillips WA, Williams DS, Shi W, Mielke LA, Ernst M, Dhillon AS, Clemons NJ, Mariadason JM. Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death Differ. 2022;29(11):2288–302.
pubmed: 35606410
pmcid: 9613692
doi: 10.1038/s41418-022-01016-w
Zhao Y, Huang X, Zhu D, Wei M, Luo J, Yu S, Tian Y, Zheng X. Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy. Cell Death Differ. 2022;29(12):2531–44.
pubmed: 35768646
pmcid: 9751275
doi: 10.1038/s41418-022-01036-6
https://gco.iarc.fr/today.
Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev. 2020;82: 101946.
pubmed: 31830641
doi: 10.1016/j.ctrv.2019.101946
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 2023;30(5):1097–154.
pubmed: 37100955
pmcid: 10130819
doi: 10.1038/s41418-023-01153-w
Lindström MS, Bartek J, Maya-Mendoza A. p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways. Cell Death Differ. 2022;29(5):972–82.
pubmed: 35444234
pmcid: 9090812
doi: 10.1038/s41418-022-00999-w
Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 2022;29(5):961–71.
pubmed: 35396345
pmcid: 9090748
doi: 10.1038/s41418-022-00996-z
Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat Commun. 2017;8(1):1315.
pubmed: 29101368
pmcid: 5670220
doi: 10.1038/s41467-017-01358-x
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, Buuren MM, van Veer L, Vincent-Salomon A, Waddell N, Yates LR, PedBrain ICGC, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR, Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.
pubmed: 23945592
pmcid: 3776390
doi: 10.1038/nature12477
Lu J, Wang XZ, Zhang TQ, Huang XY, Yao JG, Wang C, Wei ZH, Ma Y, Wu XM, Luo CY, Xia Q, Long XD. Prognostic significance of XRCC4 expression in hepatocellular carcinoma. Oncotarget. 2017;8(50):87955–70.
pubmed: 29152133
pmcid: 5675685
doi: 10.18632/oncotarget.21360
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–8.
pubmed: 23466307
doi: 10.1016/j.jhep.2013.02.022
Yang X, Smirnov A, Buonomo OC, Mauriello A, Shi Y, Bischof J, Woodsmith J, Melino G, Candi E, Bernassola F, TOR CENTRE. A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. Cell Death Discov. 2023;9(1):365.
pubmed: 37783677
pmcid: 10545677
doi: 10.1038/s41420-023-01650-4
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.
pubmed: 20644199
pmcid: 2928508
doi: 10.1101/gr.107524.110
van der Auwera G, O'Connor BD. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra. 2020: O'Reilly Media. Incorporated.
Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, Chen X, Kim Y, Beyter D, Krusche P, Saunders CT. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591–4.
pubmed: 30013048
doi: 10.1038/s41592-018-0051-x
Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283–5.
pubmed: 19542151
pmcid: 2734323
doi: 10.1093/bioinformatics/btp373
Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER, Wilson RK, Ding L. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311–7.
pubmed: 22155872
doi: 10.1093/bioinformatics/btr665
Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 2014;24(11):1881–93.
pubmed: 25060187
pmcid: 4216928
doi: 10.1101/gr.180281.114
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333–9.
pubmed: 22962449
pmcid: 3436805
doi: 10.1093/bioinformatics/bts378
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox AJ, Kruglyak S, Saunders CT. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220–2.
pubmed: 26647377
doi: 10.1093/bioinformatics/btv710
Han Y, Rovella V, Smirnov A, Buonomo OC, Mauriello A, Perretta T, Shi Y, Woodmsith J, Bischof J, Melino Candi G, Bernassola E, F TOR CENTRE. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient. Cell Death Discov. 2023;9(1):370.
pubmed: 37813891
pmcid: 10562433
doi: 10.1038/s41420-023-01651-3
Bruderer R, Sondermann J, Tsou CC, Barrantes-Freer A, Stadelmann C, Nesvizhskii AI, Schmidt M, Reiter L, Gomez-Varela D. New targeted approaches for the quantification of data-independent acquisition mass spectrometry. Proteomics. 2017. https://doi.org/10.1002/pmic.201700021 .
doi: 10.1002/pmic.201700021
pubmed: 28319648
pmcid: 5870755
Manders F, Brandsma AM, de Kanter J, Verheul M, Oka R, van Roosmalen MJ, van der Roest B, van Hoeck A, Cuppen E, van Boxtel R. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genomics. 2022;23(1):134.
pubmed: 35168570
pmcid: 8845394
doi: 10.1186/s12864-022-08357-3
Huang MN, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. MSIseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep. 2015;26(5):13321.
doi: 10.1038/srep13321
Oza VH, Fisher JL, Darji R, Lasseigne BN. CINmetrics: an R package for analyzing copy number aberrations as a measure of chromosomal instability. PeerJ. 2023;25(11): e15244.
doi: 10.7717/peerj.15244
Grendár M, Martínek P, Loderer D, Ondič O. CNHplus: the chromosomal copy number heterogeneity which respects biological constraints. BioRxiv. 2022. https://doi.org/10.1101/2022.09.30.510279 .
doi: 10.1101/2022.09.30.510279